Brief: HLS Therapeutics Comments On U.S. District Court Decision On Amarin Patents
March 31 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS COMMENTS ON U.S. DISTRICT COURT DECISION
ON
AMARIN PATENTS
* HLS THERAPEUTICS INC - SEEKS TO CLARIFY THAT THIS
LITIGATION AND
JUDGMENT DO NOT IMPACT VASCEPA IN CANADA
Source text for Eikon: ID:nCNW4SqSMa
Further company coverage: HLS.TO
((Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease